Found 96 hits with Last Name = 'priest' and Initial = 'c' Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445107
(CHEMBL3102924)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C155H248N46O46/c1-17-79(12)122(150(243)192-101(59-76(6)7)139(232)188-105(64-113(161)209)128(221)172-70-117(213)176-98(153(246)247)36-23-27-53-158)199-147(240)111(72-203)196-142(235)107(66-115(163)211)189-138(231)100(58-75(4)5)185-140(233)102(61-85-39-43-88(206)44-40-85)186-133(226)92-35-24-28-54-169-116(212)50-48-97(129(222)174-80(13)125(218)197-120(77(8)9)148(241)182-93(131(224)178-92)34-22-26-52-157)181-135(228)96(47-49-112(160)208)180-130(223)91(33-21-25-51-156)177-132(225)94(37-29-55-170-154(164)165)179-137(230)99(57-74(2)3)184-134(227)95(38-30-56-171-155(166)167)183-151(244)123(82(15)204)200-144(237)103(62-86-41-45-89(207)46-42-86)187-141(234)106(65-114(162)210)190-143(236)109(68-119(216)217)194-152(245)124(83(16)205)201-145(238)104(60-84-31-19-18-20-32-84)193-149(242)121(78(10)11)198-126(219)81(14)175-136(229)108(67-118(214)215)191-146(239)110(71-202)195-127(220)90(159)63-87-69-168-73-173-87/h18-20,31-32,39-46,69,73-83,90-111,120-124,202-207H,17,21-30,33-38,47-68,70-72,156-159H2,1-16H3,(H2,160,208)(H2,161,209)(H2,162,210)(H2,163,211)(H,168,173)(H,169,212)(H,172,221)(H,174,222)(H,175,229)(H,176,213)(H,177,225)(H,178,224)(H,179,230)(H,180,223)(H,181,228)(H,182,241)(H,183,244)(H,184,227)(H,185,233)(H,186,226)(H,187,234)(H,188,232)(H,189,231)(H,190,236)(H,191,239)(H,192,243)(H,193,242)(H,194,245)(H,195,220)(H,196,235)(H,197,218)(H,198,219)(H,199,240)(H,200,237)(H,201,238)(H,214,215)(H,216,217)(H,246,247)(H4,164,165,170)(H4,166,167,171)/t79-,80-,81-,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-,124-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445108
(CHEMBL3102923)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C155H249N47O46/c1-15-79(10)122(150(244)193-101(60-76(4)5)139(233)189-105(65-113(162)210)128(222)173-71-117(214)177-99(153(247)248)37-22-27-55-159)200-147(241)111(73-204)197-142(236)107(67-115(164)212)190-138(232)100(59-75(2)3)186-140(234)102(62-85-40-44-88(207)45-41-85)187-134(228)93(34-20-25-53-157)180-131(225)94(35-21-26-54-158)184-148(242)120(77(6)7)198-125(219)80(11)175-129(223)91-36-23-28-56-170-116(213)51-49-98(136(230)181-95(38-29-57-171-154(165)166)132(226)179-92(33-19-24-52-156)130(224)182-97(135(229)178-91)48-50-112(161)209)183-133(227)96(39-30-58-172-155(167)168)185-151(245)123(82(13)205)201-144(238)103(63-86-42-46-89(208)47-43-86)188-141(235)106(66-114(163)211)191-143(237)109(69-119(217)218)195-152(246)124(83(14)206)202-145(239)104(61-84-31-17-16-18-32-84)194-149(243)121(78(8)9)199-126(220)81(12)176-137(231)108(68-118(215)216)192-146(240)110(72-203)196-127(221)90(160)64-87-70-169-74-174-87/h16-18,31-32,40-47,70,74-83,90-111,120-124,203-208H,15,19-30,33-39,48-69,71-73,156-160H2,1-14H3,(H2,161,209)(H2,162,210)(H2,163,211)(H2,164,212)(H,169,174)(H,170,213)(H,173,222)(H,175,223)(H,176,231)(H,177,214)(H,178,229)(H,179,226)(H,180,225)(H,181,230)(H,182,224)(H,183,227)(H,184,242)(H,185,245)(H,186,234)(H,187,228)(H,188,235)(H,189,233)(H,190,232)(H,191,237)(H,192,240)(H,193,244)(H,194,243)(H,195,246)(H,196,221)(H,197,236)(H,198,219)(H,199,220)(H,200,241)(H,201,238)(H,202,239)(H,215,216)(H,217,218)(H,247,248)(H4,165,166,171)(H4,167,168,172)/t79-,80-,81-,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-,124-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.20 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445109
(CHEMBL3102922)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C158H256N46O46/c1-19-81(13)124(152(245)178-84(16)129(222)199-122(79(9)10)150(243)185-95(37-25-29-55-160)133(226)184-100(51-53-119(215)216)136(229)189-105(64-88-42-46-91(208)47-43-88)143(236)188-103(61-77(5)6)141(234)192-109(68-116(166)212)144(237)181-96(38-26-30-56-161)137(230)202-125(82(14)20-2)153(246)195-104(62-78(7)8)142(235)191-108(67-115(165)211)131(224)175-73-118(214)179-101(156(249)250)39-27-31-57-162)201-138(231)99(50-52-114(164)210)183-132(225)94(36-24-28-54-159)180-134(227)97(40-32-58-173-157(168)169)182-140(233)102(60-76(3)4)187-135(228)98(41-33-59-174-158(170)171)186-154(247)126(85(17)206)203-147(240)106(65-89-44-48-92(209)49-45-89)190-145(238)110(69-117(167)213)193-146(239)112(71-121(219)220)197-155(248)127(86(18)207)204-148(241)107(63-87-34-22-21-23-35-87)196-151(244)123(80(11)12)200-128(221)83(15)177-139(232)111(70-120(217)218)194-149(242)113(74-205)198-130(223)93(163)66-90-72-172-75-176-90/h21-23,34-35,42-49,72,75-86,93-113,122-127,205-209H,19-20,24-33,36-41,50-71,73-74,159-163H2,1-18H3,(H2,164,210)(H2,165,211)(H2,166,212)(H2,167,213)(H,172,176)(H,175,224)(H,177,232)(H,178,245)(H,179,214)(H,180,227)(H,181,237)(H,182,233)(H,183,225)(H,184,226)(H,185,243)(H,186,247)(H,187,228)(H,188,236)(H,189,229)(H,190,238)(H,191,235)(H,192,234)(H,193,239)(H,194,242)(H,195,246)(H,196,244)(H,197,248)(H,198,223)(H,199,222)(H,200,221)(H,201,231)(H,202,230)(H,203,240)(H,204,241)(H,215,216)(H,217,218)(H,219,220)(H,249,250)(H4,168,169,173)(H4,170,171,174)/t81-,82-,83-,84-,85+,86+,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-,125-,126-,127-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.210 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445110
(CHEMBL3102921)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C155H250N46O47/c1-17-79(12)122(150(244)192-101(59-76(6)7)139(233)188-105(64-113(162)209)128(222)172-70-116(212)176-98(153(247)248)36-24-28-54-159)199-147(241)111(72-203)196-142(236)107(66-115(164)211)189-138(232)100(58-75(4)5)185-140(234)102(61-85-39-43-88(206)44-40-85)186-133(227)92(34-22-26-52-157)178-131(225)93(35-23-27-53-158)182-148(242)120(77(8)9)197-125(219)80(13)174-129(223)97(48-50-117(213)214)181-135(229)96(47-49-112(161)208)180-130(224)91(33-21-25-51-156)177-132(226)94(37-29-55-170-154(165)166)179-137(231)99(57-74(2)3)184-134(228)95(38-30-56-171-155(167)168)183-151(245)123(82(15)204)200-144(238)103(62-86-41-45-89(207)46-42-86)187-141(235)106(65-114(163)210)190-143(237)109(68-119(217)218)194-152(246)124(83(16)205)201-145(239)104(60-84-31-19-18-20-32-84)193-149(243)121(78(10)11)198-126(220)81(14)175-136(230)108(67-118(215)216)191-146(240)110(71-202)195-127(221)90(160)63-87-69-169-73-173-87/h18-20,31-32,39-46,69,73-83,90-111,120-124,202-207H,17,21-30,33-38,47-68,70-72,156-160H2,1-16H3,(H2,161,208)(H2,162,209)(H2,163,210)(H2,164,211)(H,169,173)(H,172,222)(H,174,223)(H,175,230)(H,176,212)(H,177,226)(H,178,225)(H,179,231)(H,180,224)(H,181,229)(H,182,242)(H,183,245)(H,184,228)(H,185,234)(H,186,227)(H,187,235)(H,188,233)(H,189,232)(H,190,237)(H,191,240)(H,192,244)(H,193,243)(H,194,246)(H,195,221)(H,196,236)(H,197,219)(H,198,220)(H,199,241)(H,200,238)(H,201,239)(H,213,214)(H,215,216)(H,217,218)(H,247,248)(H4,165,166,170)(H4,167,168,171)/t79-,80-,81-,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-,124-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.380 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445111
(CHEMBL3102920)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C155H251N47O47/c1-15-79(10)122(150(245)193-101(60-76(4)5)139(234)189-105(65-113(163)210)128(223)173-71-116(213)177-99(153(248)249)37-23-28-56-160)200-147(242)111(73-204)197-142(237)107(67-115(165)212)190-138(233)100(59-75(2)3)186-140(235)102(62-85-40-44-88(207)45-41-85)187-134(229)93(35-21-26-54-158)180-131(226)94(36-22-27-55-159)184-148(243)120(77(6)7)198-125(220)80(11)175-129(224)91(33-19-24-52-156)178-135(230)97(48-50-112(162)209)182-130(225)92(34-20-25-53-157)179-132(227)95(38-29-57-171-154(166)167)181-136(231)98(49-51-117(214)215)183-133(228)96(39-30-58-172-155(168)169)185-151(246)123(82(13)205)201-144(239)103(63-86-42-46-89(208)47-43-86)188-141(236)106(66-114(164)211)191-143(238)109(69-119(218)219)195-152(247)124(83(14)206)202-145(240)104(61-84-31-17-16-18-32-84)194-149(244)121(78(8)9)199-126(221)81(12)176-137(232)108(68-118(216)217)192-146(241)110(72-203)196-127(222)90(161)64-87-70-170-74-174-87/h16-18,31-32,40-47,70,74-83,90-111,120-124,203-208H,15,19-30,33-39,48-69,71-73,156-161H2,1-14H3,(H2,162,209)(H2,163,210)(H2,164,211)(H2,165,212)(H,170,174)(H,173,223)(H,175,224)(H,176,232)(H,177,213)(H,178,230)(H,179,227)(H,180,226)(H,181,231)(H,182,225)(H,183,228)(H,184,243)(H,185,246)(H,186,235)(H,187,229)(H,188,236)(H,189,234)(H,190,233)(H,191,238)(H,192,241)(H,193,245)(H,194,244)(H,195,247)(H,196,222)(H,197,237)(H,198,220)(H,199,221)(H,200,242)(H,201,239)(H,202,240)(H,214,215)(H,216,217)(H,218,219)(H,248,249)(H4,166,167,171)(H4,168,169,172)/t79-,80-,81-,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-,124-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 6.60 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445112
(CHEMBL3102919)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C156H254N46O45/c1-19-80(13)122(150(242)176-83(16)127(219)197-120(78(9)10)148(240)182-95(38-26-30-54-159)131(223)179-94(37-25-29-53-158)133(225)186-103(62-87-42-46-90(207)47-43-87)140(232)185-101(59-76(5)6)138(230)189-108(67-116(165)212)142(234)196-112(73-204)147(239)200-123(81(14)20-2)151(243)192-102(60-77(7)8)139(231)188-106(65-114(163)210)129(221)173-71-117(213)177-99(154(246)247)39-27-31-55-160)199-135(227)98(50-51-113(162)209)181-130(222)93(36-24-28-52-157)178-132(224)96(40-32-56-171-155(166)167)180-137(229)100(58-75(3)4)184-134(226)97(41-33-57-172-156(168)169)183-152(244)124(84(17)205)201-144(236)104(63-88-44-48-91(208)49-45-88)187-141(233)107(66-115(164)211)190-143(235)110(69-119(216)217)194-153(245)125(85(18)206)202-145(237)105(61-86-34-22-21-23-35-86)193-149(241)121(79(11)12)198-126(218)82(15)175-136(228)109(68-118(214)215)191-146(238)111(72-203)195-128(220)92(161)64-89-70-170-74-174-89/h21-23,34-35,42-49,70,74-85,92-112,120-125,203-208H,19-20,24-33,36-41,50-69,71-73,157-161H2,1-18H3,(H2,162,209)(H2,163,210)(H2,164,211)(H2,165,212)(H,170,174)(H,173,221)(H,175,228)(H,176,242)(H,177,213)(H,178,224)(H,179,223)(H,180,229)(H,181,222)(H,182,240)(H,183,244)(H,184,226)(H,185,232)(H,186,225)(H,187,233)(H,188,231)(H,189,230)(H,190,235)(H,191,238)(H,192,243)(H,193,241)(H,194,245)(H,195,220)(H,196,234)(H,197,219)(H,198,218)(H,199,227)(H,200,239)(H,201,236)(H,202,237)(H,214,215)(H,216,217)(H,246,247)(H4,166,167,171)(H4,168,169,172)/t80-,81-,82-,83-,84+,85+,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,120-,121-,122-,123-,124-,125-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.140 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445113
(CHEMBL1981592)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O Show InChI InChI=1S/C147H237N43O43S/c1-18-75(12)115(142(229)180-96(56-72(6)7)131(218)183-104(145(232)233)63-110(155)200)188-139(226)106(68-192)185-134(221)101(62-109(154)199)177-130(217)95(55-71(4)5)174-132(219)97(58-81-37-41-84(195)42-38-81)175-125(212)88(33-23-26-49-149)167-123(210)89(34-24-27-50-150)171-140(227)113(73(8)9)186-118(205)76(13)164-121(208)93(47-53-234-17)170-127(214)92(45-46-107(152)197)169-122(209)87(32-22-25-48-148)166-124(211)90(35-28-51-161-146(156)157)168-129(216)94(54-70(2)3)173-126(213)91(36-29-52-162-147(158)159)172-143(230)116(78(15)193)189-136(223)98(59-82-39-43-85(196)44-40-82)176-133(220)100(61-108(153)198)178-135(222)103(65-112(203)204)182-144(231)117(79(16)194)190-137(224)99(57-80-30-20-19-21-31-80)181-141(228)114(74(10)11)187-119(206)77(14)165-128(215)102(64-111(201)202)179-138(225)105(67-191)184-120(207)86(151)60-83-66-160-69-163-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,191-196H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,197)(H2,153,198)(H2,154,199)(H2,155,200)(H,160,163)(H,164,208)(H,165,215)(H,166,211)(H,167,210)(H,168,216)(H,169,209)(H,170,214)(H,171,227)(H,172,230)(H,173,213)(H,174,219)(H,175,212)(H,176,220)(H,177,217)(H,178,222)(H,179,225)(H,180,229)(H,181,228)(H,182,231)(H,183,218)(H,184,207)(H,185,221)(H,186,205)(H,187,206)(H,188,226)(H,189,223)(H,190,224)(H,201,202)(H,203,204)(H,232,233)(H4,156,157,161)(H4,158,159,162)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.190 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445114
(CHEMBL3105020)Show SMILES [H][C@]1(NC(=O)[C@H](CO)NC(=O)[C@](C)(CCCC\C=C/CCCC[C@](C)(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC |r,c:17| Show InChI InChI=1S/C164H268N44O43/c1-21-90(13)128(154(244)182-93(16)133(223)201-126(88(9)10)152(242)188-105(48-34-40-66-167)136(226)185-104(47-33-39-65-166)138(228)192-113(74-97-52-56-100(213)57-53-97)143(233)191-111(71-86(5)6)150(240)208-164(20)63-37-28-26-24-23-25-27-36-62-163(19,159(250)179-81-123(217)183-109(158(248)249)49-35-41-67-168)207-151(241)112(72-87(7)8)196-155(245)129(91(14)22-2)204-149(239)120(83-210)200-160(164)251)203-140(230)108(60-61-121(170)215)187-135(225)103(46-32-38-64-165)184-137(227)106(50-42-68-177-161(172)173)186-142(232)110(70-85(3)4)190-139(229)107(51-43-69-178-162(174)175)189-156(246)130(94(17)211)205-146(236)114(75-98-54-58-101(214)59-55-98)193-144(234)116(77-122(171)216)194-145(235)118(79-125(220)221)198-157(247)131(95(18)212)206-147(237)115(73-96-44-30-29-31-45-96)197-153(243)127(89(11)12)202-132(222)92(15)181-141(231)117(78-124(218)219)195-148(238)119(82-209)199-134(224)102(169)76-99-80-176-84-180-99/h23-24,29-31,44-45,52-59,80,84-95,102-120,126-131,209-214H,21-22,25-28,32-43,46-51,60-79,81-83,165-169H2,1-20H3,(H2,170,215)(H2,171,216)(H,176,180)(H,179,250)(H,181,231)(H,182,244)(H,183,217)(H,184,227)(H,185,226)(H,186,232)(H,187,225)(H,188,242)(H,189,246)(H,190,229)(H,191,233)(H,192,228)(H,193,234)(H,194,235)(H,195,238)(H,196,245)(H,197,243)(H,198,247)(H,199,224)(H,200,251)(H,201,223)(H,202,222)(H,203,230)(H,204,239)(H,205,236)(H,206,237)(H,207,241)(H,208,240)(H,218,219)(H,220,221)(H,248,249)(H4,172,173,177)(H4,174,175,178)/b24-23-/t90-,91-,92-,93-,94+,95+,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,126-,127-,128-,129-,130-,131-,163-,164-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.390 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445115
(CHEMBL3105019)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCCC\C=C/CCCC[C@](C)(NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r,c:176| Show InChI InChI=1S/C163H263N45O44/c1-21-87(13)127(153(245)182-90(16)132(224)201-125(85(9)10)151(243)188-103(45-33-38-62-165)149(241)207-162(19)59-35-27-25-23-24-26-28-36-60-163(20,208-150(242)114(75-121(171)217)194-141(233)107(67-83(5)6)190-143(235)111(200-158(162)251)71-95-51-55-98(213)56-52-95)159(252)206-128(88(14)22-2)154(246)196-108(68-84(7)8)142(234)192-112(73-119(169)215)134(226)179-79-122(218)183-105(157(249)250)46-34-39-63-166)203-138(230)104(57-58-118(168)214)186-135(227)100(44-32-37-61-164)184-136(228)101(47-40-64-177-160(172)173)185-140(232)106(66-82(3)4)189-137(229)102(48-41-65-178-161(174)175)187-155(247)129(91(17)210)204-146(238)109(70-94-49-53-97(212)54-50-94)191-144(236)113(74-120(170)216)193-145(237)116(77-124(221)222)198-156(248)130(92(18)211)205-147(239)110(69-93-42-30-29-31-43-93)197-152(244)126(86(11)12)202-131(223)89(15)181-139(231)115(76-123(219)220)195-148(240)117(80-209)199-133(225)99(167)72-96-78-176-81-180-96/h23-24,29-31,42-43,49-56,78,81-92,99-117,125-130,209-213H,21-22,25-28,32-41,44-48,57-77,79-80,164-167H2,1-20H3,(H2,168,214)(H2,169,215)(H2,170,216)(H2,171,217)(H,176,180)(H,179,226)(H,181,231)(H,182,245)(H,183,218)(H,184,228)(H,185,232)(H,186,227)(H,187,247)(H,188,243)(H,189,229)(H,190,235)(H,191,236)(H,192,234)(H,193,237)(H,194,233)(H,195,240)(H,196,246)(H,197,244)(H,198,248)(H,199,225)(H,200,251)(H,201,224)(H,202,223)(H,203,230)(H,204,238)(H,205,239)(H,206,252)(H,207,241)(H,208,242)(H,219,220)(H,221,222)(H,249,250)(H4,172,173,177)(H4,174,175,178)/b24-23-/t87-,88-,89-,90-,91+,92+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,125-,126-,127-,128-,129-,130-,162-,163-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.5 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445116
(CHEMBL3102931)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@]1(C)CCCC\C=C/CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r,c:49| Show InChI InChI=1S/C160H257N45O45/c1-19-85(12)125(151(244)193-105(65-82(6)7)138(231)189-109(70-117(166)213)131(224)176-76-120(216)180-102(154(247)248)43-31-36-60-163)201-146(239)115(78-207)197-141(234)111(72-119(168)215)190-137(230)104(64-81(4)5)187-139(232)108(68-92-48-52-95(211)53-49-92)198-156(250)160(18)57-33-25-23-21-20-22-24-32-56-159(17,155(249)179-87(14)129(222)200-123(83(8)9)149(242)185-100(147(240)204-160)42-30-35-59-162)205-148(241)101(54-55-116(165)212)183-132(225)97(41-29-34-58-161)181-133(226)98(44-37-61-174-157(169)170)182-136(229)103(63-80(2)3)186-134(227)99(45-38-62-175-158(171)172)184-152(245)126(88(15)208)202-143(236)106(67-91-46-50-94(210)51-47-91)188-140(233)110(71-118(167)214)191-142(235)113(74-122(219)220)195-153(246)127(89(16)209)203-144(237)107(66-90-39-27-26-28-40-90)194-150(243)124(84(10)11)199-128(221)86(13)178-135(228)112(73-121(217)218)192-145(238)114(77-206)196-130(223)96(164)69-93-75-173-79-177-93/h20-21,26-28,39-40,46-53,75,79-89,96-115,123-127,206-211H,19,22-25,29-38,41-45,54-74,76-78,161-164H2,1-18H3,(H2,165,212)(H2,166,213)(H2,167,214)(H2,168,215)(H,173,177)(H,176,224)(H,178,228)(H,179,249)(H,180,216)(H,181,226)(H,182,229)(H,183,225)(H,184,245)(H,185,242)(H,186,227)(H,187,232)(H,188,233)(H,189,231)(H,190,230)(H,191,235)(H,192,238)(H,193,244)(H,194,243)(H,195,246)(H,196,223)(H,197,234)(H,198,250)(H,199,221)(H,200,222)(H,201,239)(H,202,236)(H,203,237)(H,204,240)(H,205,241)(H,217,218)(H,219,220)(H,247,248)(H4,169,170,174)(H4,171,172,175)/b21-20-/t85-,86-,87-,88+,89+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,123-,124-,125-,126-,127-,159-,160-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.330 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445117
(CHEMBL3102930)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@]1(C)CCCC\C=C/CCCC[C@](C)(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r,c:76| Show InChI InChI=1S/C160H258N46O45/c1-17-85(10)125(151(245)194-105(66-82(4)5)138(232)190-109(71-117(167)214)131(225)177-77-120(217)181-103(154(248)249)44-30-36-62-164)202-146(240)115(79-208)198-141(235)111(73-119(169)216)191-137(231)104(65-81(2)3)187-139(233)106(68-91-47-51-94(211)52-48-91)188-134(228)98(42-28-34-60-162)182-133(227)99(43-29-35-61-163)185-149(243)123(83(6)7)201-129(223)87(12)180-155(250)159(15)57-31-22-20-18-19-21-23-32-58-160(16,156(251)199-100(45-37-63-175-157(170)171)135(229)183-97(41-27-33-59-161)132(226)184-102(148(242)206-159)55-56-116(166)213)205-147(241)101(46-38-64-176-158(172)173)186-152(246)126(88(13)209)203-143(237)107(69-92-49-53-95(212)54-50-92)189-140(234)110(72-118(168)215)192-142(236)113(75-122(220)221)196-153(247)127(89(14)210)204-144(238)108(67-90-39-25-24-26-40-90)195-150(244)124(84(8)9)200-128(222)86(11)179-136(230)112(74-121(218)219)193-145(239)114(78-207)197-130(224)96(165)70-93-76-174-80-178-93/h18-19,24-26,39-40,47-54,76,80-89,96-115,123-127,207-212H,17,20-23,27-38,41-46,55-75,77-79,161-165H2,1-16H3,(H2,166,213)(H2,167,214)(H2,168,215)(H2,169,216)(H,174,178)(H,177,225)(H,179,230)(H,180,250)(H,181,217)(H,182,227)(H,183,229)(H,184,226)(H,185,243)(H,186,246)(H,187,233)(H,188,228)(H,189,234)(H,190,232)(H,191,231)(H,192,236)(H,193,239)(H,194,245)(H,195,244)(H,196,247)(H,197,224)(H,198,235)(H,199,251)(H,200,222)(H,201,223)(H,202,240)(H,203,237)(H,204,238)(H,205,241)(H,206,242)(H,218,219)(H,220,221)(H,248,249)(H4,170,171,175)(H4,172,173,176)/b19-18-/t85-,86-,87-,88+,89+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,123-,124-,125-,126-,127-,159-,160-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.0500 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445118
(CHEMBL3102929)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C)(CCCC=C)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C164H268N44O43/c1-23-27-36-62-163(21,159(250)179-81-123(217)183-109(158(248)249)49-35-41-67-168)207-151(241)112(72-87(9)10)196-155(245)129(91(16)26-4)204-149(239)120(83-210)200-160(251)164(22,63-37-28-24-2)208-150(240)111(71-86(7)8)191-143(233)113(74-97-52-56-100(213)57-53-97)192-138(228)104(47-33-39-65-166)185-136(226)105(48-34-40-66-167)188-152(242)126(88(11)12)201-133(223)93(18)182-154(244)128(90(15)25-3)203-140(230)108(60-61-121(170)215)187-135(225)103(46-32-38-64-165)184-137(227)106(50-42-68-177-161(172)173)186-142(232)110(70-85(5)6)190-139(229)107(51-43-69-178-162(174)175)189-156(246)130(94(19)211)205-146(236)114(75-98-54-58-101(214)59-55-98)193-144(234)116(77-122(171)216)194-145(235)118(79-125(220)221)198-157(247)131(95(20)212)206-147(237)115(73-96-44-30-29-31-45-96)197-153(243)127(89(13)14)202-132(222)92(17)181-141(231)117(78-124(218)219)195-148(238)119(82-209)199-134(224)102(169)76-99-80-176-84-180-99/h23-24,29-31,44-45,52-59,80,84-95,102-120,126-131,209-214H,1-2,25-28,32-43,46-51,60-79,81-83,165-169H2,3-22H3,(H2,170,215)(H2,171,216)(H,176,180)(H,179,250)(H,181,231)(H,182,244)(H,183,217)(H,184,227)(H,185,226)(H,186,232)(H,187,225)(H,188,242)(H,189,246)(H,190,229)(H,191,233)(H,192,228)(H,193,234)(H,194,235)(H,195,238)(H,196,245)(H,197,243)(H,198,247)(H,199,224)(H,200,251)(H,201,223)(H,202,222)(H,203,230)(H,204,239)(H,205,236)(H,206,237)(H,207,241)(H,208,240)(H,218,219)(H,220,221)(H,248,249)(H4,172,173,177)(H4,174,175,178)/t90-,91-,92-,93-,94+,95+,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,126-,127-,128-,129-,130-,131-,163-,164-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.210 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445119
(CHEMBL3102928)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C163H263N45O44/c1-23-27-35-59-162(21,158(251)200-111(71-95-51-55-98(213)56-52-95)143(235)190-107(67-83(7)8)141(233)194-114(75-121(171)217)150(242)208-163(22,60-36-28-24-2)159(252)206-128(88(16)26-4)154(246)196-108(68-84(9)10)142(234)192-112(73-119(169)215)134(226)179-79-122(218)183-105(157(249)250)46-34-39-63-166)207-149(241)103(45-33-38-62-165)188-151(243)125(85(11)12)201-132(224)90(18)182-153(245)127(87(15)25-3)203-138(230)104(57-58-118(168)214)186-135(227)100(44-32-37-61-164)184-136(228)101(47-40-64-177-160(172)173)185-140(232)106(66-82(5)6)189-137(229)102(48-41-65-178-161(174)175)187-155(247)129(91(19)210)204-146(238)109(70-94-49-53-97(212)54-50-94)191-144(236)113(74-120(170)216)193-145(237)116(77-124(221)222)198-156(248)130(92(20)211)205-147(239)110(69-93-42-30-29-31-43-93)197-152(244)126(86(13)14)202-131(223)89(17)181-139(231)115(76-123(219)220)195-148(240)117(80-209)199-133(225)99(167)72-96-78-176-81-180-96/h23-24,29-31,42-43,49-56,78,81-92,99-117,125-130,209-213H,1-2,25-28,32-41,44-48,57-77,79-80,164-167H2,3-22H3,(H2,168,214)(H2,169,215)(H2,170,216)(H2,171,217)(H,176,180)(H,179,226)(H,181,231)(H,182,245)(H,183,218)(H,184,228)(H,185,232)(H,186,227)(H,187,247)(H,188,243)(H,189,229)(H,190,235)(H,191,236)(H,192,234)(H,193,237)(H,194,233)(H,195,240)(H,196,246)(H,197,244)(H,198,248)(H,199,225)(H,200,251)(H,201,224)(H,202,223)(H,203,230)(H,204,238)(H,205,239)(H,206,252)(H,207,241)(H,208,242)(H,219,220)(H,221,222)(H,249,250)(H4,172,173,177)(H4,174,175,178)/t87-,88-,89-,90-,91+,92+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,125-,126-,127-,128-,129-,130-,162-,163-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 3.80 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445120
(CHEMBL3102927)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C160H257N45O45/c1-21-24-32-56-159(19,155(249)179-87(16)129(222)200-123(83(10)11)149(242)185-100(42-30-35-59-162)147(240)204-160(20,57-33-25-22-2)156(250)198-108(68-92-48-52-95(211)53-49-92)139(232)187-104(64-81(6)7)137(230)190-111(72-119(168)215)141(234)197-115(78-207)146(239)201-125(85(14)23-3)151(244)193-105(65-82(8)9)138(231)189-109(70-117(166)213)131(224)176-76-120(216)180-102(154(247)248)43-31-36-60-163)205-148(241)101(54-55-116(165)212)183-132(225)97(41-29-34-58-161)181-133(226)98(44-37-61-174-157(169)170)182-136(229)103(63-80(4)5)186-134(227)99(45-38-62-175-158(171)172)184-152(245)126(88(17)208)202-143(236)106(67-91-46-50-94(210)51-47-91)188-140(233)110(71-118(167)214)191-142(235)113(74-122(219)220)195-153(246)127(89(18)209)203-144(237)107(66-90-39-27-26-28-40-90)194-150(243)124(84(12)13)199-128(221)86(15)178-135(228)112(73-121(217)218)192-145(238)114(77-206)196-130(223)96(164)69-93-75-173-79-177-93/h21-22,26-28,39-40,46-53,75,79-89,96-115,123-127,206-211H,1-2,23-25,29-38,41-45,54-74,76-78,161-164H2,3-20H3,(H2,165,212)(H2,166,213)(H2,167,214)(H2,168,215)(H,173,177)(H,176,224)(H,178,228)(H,179,249)(H,180,216)(H,181,226)(H,182,229)(H,183,225)(H,184,245)(H,185,242)(H,186,227)(H,187,232)(H,188,233)(H,189,231)(H,190,230)(H,191,235)(H,192,238)(H,193,244)(H,194,243)(H,195,246)(H,196,223)(H,197,234)(H,198,250)(H,199,221)(H,200,222)(H,201,239)(H,202,236)(H,203,237)(H,204,240)(H,205,241)(H,217,218)(H,219,220)(H,247,248)(H4,169,170,174)(H4,171,172,175)/t85-,86-,87-,88+,89+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,123-,124-,125-,126-,127-,159-,160-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.5 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445121
(CHEMBL3102926)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C160H258N46O45/c1-19-22-31-57-159(17,155(250)180-87(14)129(223)201-123(83(8)9)149(243)185-99(43-29-35-61-163)133(227)182-98(42-28-34-60-162)134(228)188-106(68-91-47-51-94(211)52-48-91)139(233)187-104(65-81(4)5)137(231)191-111(73-119(169)216)141(235)198-115(79-208)146(240)202-125(85(12)21-3)151(245)194-105(66-82(6)7)138(232)190-109(71-117(167)214)131(225)177-77-120(217)181-103(154(248)249)44-30-36-62-164)206-148(242)102(55-56-116(166)213)184-132(226)97(41-27-33-59-161)183-135(229)100(45-37-63-175-157(170)171)199-156(251)160(18,58-32-23-20-2)205-147(241)101(46-38-64-176-158(172)173)186-152(246)126(88(15)209)203-143(237)107(69-92-49-53-95(212)54-50-92)189-140(234)110(72-118(168)215)192-142(236)113(75-122(220)221)196-153(247)127(89(16)210)204-144(238)108(67-90-39-25-24-26-40-90)195-150(244)124(84(10)11)200-128(222)86(13)179-136(230)112(74-121(218)219)193-145(239)114(78-207)197-130(224)96(165)70-93-76-174-80-178-93/h19-20,24-26,39-40,47-54,76,80-89,96-115,123-127,207-212H,1-2,21-23,27-38,41-46,55-75,77-79,161-165H2,3-18H3,(H2,166,213)(H2,167,214)(H2,168,215)(H2,169,216)(H,174,178)(H,177,225)(H,179,230)(H,180,250)(H,181,217)(H,182,227)(H,183,229)(H,184,226)(H,185,243)(H,186,246)(H,187,233)(H,188,228)(H,189,234)(H,190,232)(H,191,231)(H,192,236)(H,193,239)(H,194,245)(H,195,244)(H,196,247)(H,197,224)(H,198,235)(H,199,251)(H,200,222)(H,201,223)(H,202,240)(H,203,237)(H,204,238)(H,205,241)(H,206,242)(H,218,219)(H,220,221)(H,248,249)(H4,170,171,175)(H4,172,173,176)/t85-,86-,87-,88+,89+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,123-,124-,125-,126-,127-,159-,160-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.40 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Vasoactive intestinal polypeptide receptor 2
(Homo sapiens (Human)) | BDBM50445122
(CHEMBL3102925)Show SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O |r| Show InChI InChI=1S/C158H254N46O45/c1-19-81(13)124(152(244)178-84(16)129(221)199-122(79(9)10)150(242)185-95(37-25-29-55-160)133(225)184-100-51-53-118(214)172-57-31-27-38-96(181-144(236)109(68-116(165)212)192-141(233)103(61-77(5)6)188-143(235)105(189-136(100)228)64-88-42-46-91(208)47-43-88)137(229)202-125(82(14)20-2)153(245)195-104(62-78(7)8)142(234)191-108(67-115(164)211)131(223)175-73-119(215)179-101(156(248)249)39-26-30-56-161)201-138(230)99(50-52-114(163)210)183-132(224)94(36-24-28-54-159)180-134(226)97(40-32-58-173-157(167)168)182-140(232)102(60-76(3)4)187-135(227)98(41-33-59-174-158(169)170)186-154(246)126(85(17)206)203-147(239)106(65-89-44-48-92(209)49-45-89)190-145(237)110(69-117(166)213)193-146(238)112(71-121(218)219)197-155(247)127(86(18)207)204-148(240)107(63-87-34-22-21-23-35-87)196-151(243)123(80(11)12)200-128(220)83(15)177-139(231)111(70-120(216)217)194-149(241)113(74-205)198-130(222)93(162)66-90-72-171-75-176-90/h21-23,34-35,42-49,72,75-86,93-113,122-127,205-209H,19-20,24-33,36-41,50-71,73-74,159-162H2,1-18H3,(H2,163,210)(H2,164,211)(H2,165,212)(H2,166,213)(H,171,176)(H,172,214)(H,175,223)(H,177,231)(H,178,244)(H,179,215)(H,180,226)(H,181,236)(H,182,232)(H,183,224)(H,184,225)(H,185,242)(H,186,246)(H,187,227)(H,188,235)(H,189,228)(H,190,237)(H,191,234)(H,192,233)(H,193,238)(H,194,241)(H,195,245)(H,196,243)(H,197,247)(H,198,222)(H,199,221)(H,200,220)(H,201,230)(H,202,229)(H,203,239)(H,204,240)(H,216,217)(H,218,219)(H,248,249)(H4,167,168,173)(H4,169,170,174)/t81-,82-,83-,84-,85+,86+,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-,125-,126-,127-/m0/s1 | PDB
MMDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.110 | n/a | n/a | n/a | n/a |
AstraZeneca
Curated by ChEMBL
| Assay Description
Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay |
ACS Med Chem Lett 4: 1163-8 (2013)
Article DOI: 10.1021/ml400257h
BindingDB Entry DOI: 10.7270/Q27P90V9 |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268715
(CHEMBL4090221)Show InChI InChI=1S/C17H21NO2S/c1-4-18(12-16-6-5-11-21-16)17(19)14(3)20-15-9-7-13(2)8-10-15/h5-11,14H,4,12H2,1-3H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 889 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268716
(CHEMBL4069157)Show InChI InChI=1S/C18H23NO2S/c1-5-19(13-16-7-6-12-22-16)17(20)18(3,4)21-15-10-8-14(2)9-11-15/h6-12H,5,13H2,1-4H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.10E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268717
(CHEMBL4091126)Show InChI InChI=1S/C17H21NOS/c1-3-18(13-16-5-4-12-20-16)17(19)11-10-15-8-6-14(2)7-9-15/h4-9,12H,3,10-11,13H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 93 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268718
(CHEMBL4071883)Show InChI InChI=1S/C16H19NO2S/c1-2-17(12-14-9-6-10-20-14)16(19)11-15(18)13-7-4-3-5-8-13/h3-10,15,18H,2,11-12H2,1H3/t15-/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 5.20E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268719
(CHEMBL4093598)Show InChI InChI=1S/C17H17NO2S/c1-3-18(11-14-5-4-8-21-14)17(19)16-10-13-9-12(2)6-7-15(13)20-16/h4-10H,3,11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 120 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268720
(CHEMBL4067021)Show InChI InChI=1S/C17H17NOS2/c1-3-18(11-14-5-4-8-20-14)17(19)16-10-13-9-12(2)6-7-15(13)21-16/h4-10H,3,11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268722
(CHEMBL4086590)Show InChI InChI=1S/C16H19NO3/c1-3-17(11-15-5-4-10-19-15)16(18)12-20-14-8-6-13(2)7-9-14/h4-10H,3,11-12H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Patents
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 489 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268723
(CHEMBL4093292)Show InChI InChI=1S/C16H20N2O2/c1-3-18(11-14-8-9-17-10-14)16(19)12-20-15-6-4-13(2)5-7-15/h4-10,17H,3,11-12H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 2.18E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268724
(CHEMBL4091381)Show InChI InChI=1S/C17H17N3O3S/c1-22-13-4-6-14(7-5-13)23-12-17(21)20(16-8-9-18-19-16)11-15-3-2-10-24-15/h2-10H,11-12H2,1H3,(H,18,19) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 3.70 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268728
(CHEMBL4087469)Show InChI InChI=1S/C17H17NO3S/c1-3-18(11-14-5-4-8-22-14)17(19)16-10-12-9-13(20-2)6-7-15(12)21-16/h4-10H,3,11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 80 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268729
(CHEMBL4060261)Show SMILES COc1ccc2oc(cc2c1)C(=O)N(Cc1cccs1)c1ccn[nH]1 Show InChI InChI=1S/C18H15N3O3S/c1-23-13-4-5-15-12(9-13)10-16(24-15)18(22)21(17-6-7-19-20-17)11-14-3-2-8-25-14/h2-10H,11H2,1H3,(H,19,20) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.10 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268730
(CHEMBL4091183)Show InChI InChI=1S/C18H15N3O2S/c1-12-4-5-15-13(9-12)10-16(23-15)18(22)21(17-6-7-19-20-17)11-14-3-2-8-24-14/h2-10H,11H2,1H3,(H,19,20) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 40 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268731
(CHEMBL4098555)Show InChI InChI=1S/C14H18N4O2/c1-3-18(9-12-8-15-17-16-12)14(19)10-20-13-6-4-11(2)5-7-13/h4-8H,3,9-10H2,1-2H3,(H,15,16,17) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 3.11E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268732
(CHEMBL4062900)Show InChI InChI=1S/C18H21NO2/c1-3-19(13-16-7-5-4-6-8-16)18(20)14-21-17-11-9-15(2)10-12-17/h4-12H,3,13-14H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.88E+3 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268733
(CHEMBL4090832)Show InChI InChI=1S/C17H20N2O2/c1-3-19(12-15-6-4-5-11-18-15)17(20)13-21-16-9-7-14(2)8-10-16/h4-11H,3,12-13H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.60E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268734
(CHEMBL4066698)Show InChI InChI=1S/C17H20N2O2/c1-3-19(12-15-5-4-10-18-11-15)17(20)13-21-16-8-6-14(2)7-9-16/h4-11H,3,12-13H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.54E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268735
(CHEMBL4059464)Show InChI InChI=1S/C16H19NO3S/c1-3-17(10-13-5-4-8-21-13)16(19)11-20-15-9-12(2)6-7-14(15)18/h4-9,18H,3,10-11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 24 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268745
(CHEMBL4087060)Show InChI InChI=1S/C16H19NO3S/c1-3-17(10-13-5-4-8-21-13)16(19)11-20-15-7-6-12(2)9-14(15)18/h4-9,18H,3,10-11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Patents
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 8 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268746
(CHEMBL4097943)Show InChI InChI=1S/C17H17NO3S/c1-2-18(11-14-4-3-9-22-14)17(19)8-6-13-5-7-15-16(10-13)21-12-20-15/h3-10H,2,11-12H2,1H3/b8-6+ | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.700 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268747
(CHEMBL4070838)Show InChI InChI=1S/C18H17N3OS/c1-14-4-6-15(7-5-14)8-9-18(22)21(17-10-11-19-20-17)13-16-3-2-12-23-16/h2-12H,13H2,1H3,(H,19,20)/b9-8+ | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.00400 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268748
(CHEMBL4069241)Show SMILES O=C(\C=C\c1ccc2OCOc2c1)N(Cc1cccs1)c1ccn[nH]1 Show InChI InChI=1S/C18H15N3O3S/c22-18(6-4-13-3-5-15-16(10-13)24-12-23-15)21(17-7-8-19-20-17)11-14-2-1-9-25-14/h1-10H,11-12H2,(H,19,20)/b6-4+ | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268749
(CHEMBL4097005)Show InChI InChI=1S/C17H15N3O4S/c21-17(10-22-12-3-4-14-15(8-12)24-11-23-14)20(16-5-6-18-19-16)9-13-2-1-7-25-13/h1-8H,9-11H2,(H,18,19) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.600 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268750
(CHEMBL4064391)Show InChI InChI=1S/C19H19N3O2S/c23-19(13-24-16-7-6-14-3-1-4-15(14)11-16)22(18-8-9-20-21-18)12-17-5-2-10-25-17/h2,5-11H,1,3-4,12-13H2,(H,20,21) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 0.00100 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268751
(CHEMBL4065074)Show InChI InChI=1S/C17H21NO3S/c1-14-5-7-15(8-6-14)21-13-17(20)18(9-3-10-19)12-16-4-2-11-22-16/h2,4-8,11,19H,3,9-10,12-13H2,1H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 3.00E+3 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268752
(CHEMBL4086513)Show InChI InChI=1S/C17H21NO3S/c1-14-5-7-15(8-6-14)21-13-17(19)18(9-10-20-2)12-16-4-3-11-22-16/h3-8,11H,9-10,12-13H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 400 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268753
(CHEMBL4100340)Show InChI InChI=1S/C15H17NO2S/c1-12-5-7-13(8-6-12)18-11-15(17)16(2)10-14-4-3-9-19-14/h3-9H,10-11H2,1-2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 400 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268754
(CHEMBL1457614)Show InChI InChI=1S/C14H15NO2S/c1-11-4-6-12(7-5-11)17-10-14(16)15-9-13-3-2-8-18-13/h2-8H,9-10H2,1H3,(H,15,16) | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| Purchase
PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 2.50E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268755
(CHEMBL4067932)Show InChI InChI=1S/C20H25NO2S/c1-16-9-11-18(12-10-16)23-15-20(22)21(14-19-8-5-13-24-19)17-6-3-2-4-7-17/h5,8-13,17H,2-4,6-7,14-15H2,1H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 4.00E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268756
(CHEMBL4092493)Show InChI InChI=1S/C17H19NO2S/c1-3-10-18(12-16-5-4-11-21-16)17(19)13-20-15-8-6-14(2)7-9-15/h3-9,11H,1,10,12-13H2,2H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 20 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268757
(CHEMBL4084023)Show InChI InChI=1S/C18H23NO2S/c1-4-15(3)19(12-17-6-5-11-22-17)18(20)13-21-16-9-7-14(2)8-10-16/h5-11,15H,4,12-13H2,1-3H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268760
(CHEMBL4102011)Show InChI InChI=1S/C18H23NO2S/c1-14-7-9-15(10-8-14)21-13-17(20)19(18(2,3)4)12-16-6-5-11-22-16/h5-11H,12-13H2,1-4H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 1.10E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268761
(CHEMBL4091795)Show InChI InChI=1S/C17H19NO3S/c1-13-4-6-15(7-5-13)21-12-17(19)18(14-10-20-11-14)9-16-3-2-8-22-16/h2-8,14H,9-12H2,1H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| Article
PubMed
| n/a | n/a | n/a | n/a | 2.30E+4 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268762
(CHEMBL4091813)Show InChI InChI=1S/C20H19NO2S/c1-16-9-11-18(12-10-16)23-15-20(22)21(14-19-8-5-13-24-19)17-6-3-2-4-7-17/h2-13H,14-15H2,1H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 23 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Transient receptor potential cation channel subfamily M member 8
(Homo sapiens (Human)) | BDBM50268763
(CHEMBL4064052)Show InChI InChI=1S/C17H16N2O3S/c1-13-4-6-14(7-5-13)21-12-17(20)19(16-8-9-22-18-16)11-15-3-2-10-23-15/h2-10H,11-12H2,1H3 | PDB
KEGG
UniProtKB/SwissProt
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | n/a | n/a | 2 | n/a | n/a | n/a | n/a |
Senomyx Inc., 4767 Nexus Centre Dr, San Diego, CA 92121, United States.
Curated by ChEMBL
| Assay Description
Agonist activity at human TRPM8 expressed in HEK293 cells assessed as increase in intracellular calcium level after 15 mins by Fluo-3-AM dye-based fl... |
Bioorg Med Chem Lett 27: 3931-3938 (2017)
Article DOI: 10.1016/j.bmcl.2017.04.003
BindingDB Entry DOI: 10.7270/Q25H7JRG |
More data for this
Ligand-Target Pair | |
Search and Browse
